{"id":19803,"date":"2018-11-27T04:52:12","date_gmt":"2018-11-27T04:52:12","guid":{"rendered":"https:\/\/arisglobal.com\/bkp-site\/?p=19803"},"modified":"2018-11-27T04:52:12","modified_gmt":"2018-11-27T04:52:12","slug":"fda-selects-arisglobal-next-generation-safety-platform-lifesphere-multivigilance","status":"publish","type":"post","link":"https:\/\/www.arisglobal.com\/media\/press-release\/fda-selects-arisglobal-next-generation-safety-platform-lifesphere-multivigilance\/","title":{"rendered":"FDA Selects ArisGlobal’s Next-Generation LifeSphere Safety and Medical Affairs Platform"},"content":{"rendered":"

FDA Selects LifeSphere MultiVigilance, Medical Information, and Product Complaints as Components of Their New Integrated Safety Platform <\/em><\/strong><\/p>\n

MIAMI, FL. November 27, 2018 \u2013 <\/strong>The U.S. Food and Drug Administration<\/a> (FDA) has selected Booz Allen Hamilton to support development, modernization, and enhancement of the FDA Adverse Event Reporting System (FAERS). As part of this work, the Agency will deploy ArisGlobal\u2019s LifeSphere MultiVigilance<\/strong> (LSMV) platform to replace part of its current pharmacovigilance system that will intake, triage and process safety reports and make them available for review and analysis. LSMV will deliver the assured compliance, configurability, and flexibility needed to meet its growing responsibilities for protecting public health and safety. ArisGlobal\u2019s LifeSphere Product Complaints<\/strong> and Medical Information<\/strong> will provide end-to-end processing of product quality defect reports, as well as tracking and responding efficiently to inquiries.<\/p>\n

LSMV is the next-generation safety system from ArisGlobal. It combines artificial intelligence (AI) with robotic process automation (RPA) to help organizations streamline case processing and medical review, substantially reducing manual effort. This new platform will be transformative for FDA in its ability to automate process, incorporate latest safety data standards and improve productivity resulting in reviewers to focus on public health and\u00a0patient safety.<\/p>\n

\u201cBooz Allen is proud to support the FDA\u2019s mission to protect public health by strengthening the Agency\u2019s pre- and post-market surveillance operations. Our multidisciplinary team of drug safety domain experts and technologists will be responsible for providing the FDA an integrated and modernized suite of capabilities to protect consumers from unsafe and\/or ineffective products.,\u201d said Sean Chaffee, Booz Allen Hamilton FAERS Program Lead. \u201cThis transformational work will fundamentally improve health outcomes and positively impact mission performance.\u201d<\/p><\/blockquote>\n

\u201cWe are delighted that our recently launched unified platform for drug safety, medical information and product quality complaints has been selected by FDA.\u201d said Sankesh Abbhi<\/a>, President and CEO, ArisGlobal.\u00a0\u201cComplementing the platform, our Regulatory Authority Standard\u00a0Practices\u00a0(RASP) initiative allows us to\u00a0fully understand the needs and expectations of the regulatory health authorities. With the addition of the FDA, nine\u00a0major authorities\u00a0now\u00a0rely on ArisGlobal solutions to protect public health.\u201d<\/p><\/blockquote>\n

Learn more:<\/strong>\u00a0 LifeSphere MultiVigilance<\/a><\/p>\n

Learn more:<\/strong>\u00a0 LifeSphere Medical Information<\/a><\/p>\n

Learn more:<\/strong>\u00a0 LifeSphere Product Complaints<\/a><\/p>\n

<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

The U.S. Food and Drug Administration (FDA) has selected Booz Allen Hamilton to support development, modernization, and enhancement of the FDA Adverse Event Reporting System (FAERS). As part of this work, the Agency will deploy ArisGlobal\u2019s LifeSphere MultiVigilance (LSMV) platform to replace part of its current pharmacovigilance system that will intake, triage and process safety reports and make them available for review and analysis.<\/p>\n","protected":false},"author":27,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[65],"tags":[],"class_list":["post-19803","post","type-post","status-publish","format-standard","hentry","category-press-release"],"acf":[],"yoast_head":"\nFDA Selects ArisGlobal's Next-Gen Safety Platform LifeSphere MultiVigilance | ArisGlobal<\/title>\n<meta name=\"description\" content=\"The U.S. FDA selects ArisGlobal\u2019s LifeSphere MultiVigilance drug safety platform to support modernization & enhancement of the FDA Adverse Event Reporting System (FAERS)\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.arisglobal.com\/media\/press-release\/fda-selects-arisglobal-next-generation-safety-platform-lifesphere-multivigilance\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Selects ArisGlobal's Next-Generation LifeSphere Safety and Medical Affairs Platform\" \/>\n<meta property=\"og:description\" content=\"The U.S. FDA selects ArisGlobal\u2019s LifeSphere MultiVigilance drug safety platform to support modernization & enhancement of the FDA Adverse Event Reporting System (FAERS)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.arisglobal.com\/media\/press-release\/fda-selects-arisglobal-next-generation-safety-platform-lifesphere-multivigilance\/\" \/>\n<meta property=\"og:site_name\" content=\"ArisGlobal\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LifeSphereAG\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-11-27T04:52:12+00:00\" \/>\n<meta name=\"author\" content=\"Mladen Prenc\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mladen Prenc\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.arisglobal.com\/media\/press-release\/fda-selects-arisglobal-next-generation-safety-platform-lifesphere-multivigilance\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.arisglobal.com\/media\/press-release\/fda-selects-arisglobal-next-generation-safety-platform-lifesphere-multivigilance\/\"},\"author\":{\"name\":\"Mladen Prenc\",\"@id\":\"https:\/\/www.arisglobal.com\/#\/schema\/person\/bb2c7aafe44a090bcd667448651eb974\"},\"headline\":\"FDA Selects ArisGlobal’s Next-Generation LifeSphere Safety and Medical Affairs Platform\",\"datePublished\":\"2018-11-27T04:52:12+00:00\",\"dateModified\":\"2018-11-27T04:52:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.arisglobal.com\/media\/press-release\/fda-selects-arisglobal-next-generation-safety-platform-lifesphere-multivigilance\/\"},\"wordCount\":373,\"publisher\":{\"@id\":\"https:\/\/www.arisglobal.com\/#organization\"},\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.arisglobal.com\/media\/press-release\/fda-selects-arisglobal-next-generation-safety-platform-lifesphere-multivigilance\/\",\"url\":\"https:\/\/www.arisglobal.com\/media\/press-release\/fda-selects-arisglobal-next-generation-safety-platform-lifesphere-multivigilance\/\",\"name\":\"FDA Selects ArisGlobal's Next-Gen Safety Platform LifeSphere MultiVigilance | ArisGlobal\",\"isPartOf\":{\"@id\":\"https:\/\/www.arisglobal.com\/#website\"},\"datePublished\":\"2018-11-27T04:52:12+00:00\",\"dateModified\":\"2018-11-27T04:52:12+00:00\",\"description\":\"The U.S. FDA selects ArisGlobal\u2019s LifeSphere MultiVigilance drug safety platform to support modernization & enhancement of the FDA Adverse Event Reporting System (FAERS)\",\"breadcrumb\":{\"@id\":\"https:\/\/www.arisglobal.com\/media\/press-release\/fda-selects-arisglobal-next-generation-safety-platform-lifesphere-multivigilance\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.arisglobal.com\/media\/press-release\/fda-selects-arisglobal-next-generation-safety-platform-lifesphere-multivigilance\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.arisglobal.com\/media\/press-release\/fda-selects-arisglobal-next-generation-safety-platform-lifesphere-multivigilance\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.arisglobal.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Selects ArisGlobal’s Next-Generation LifeSphere Safety and Medical Affairs Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.arisglobal.com\/#website\",\"url\":\"https:\/\/www.arisglobal.com\/\",\"name\":\"ArisGlobal\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.arisglobal.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.arisglobal.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.arisglobal.com\/#organization\",\"name\":\"LifeSphere\",\"url\":\"https:\/\/www.arisglobal.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arisglobal.com\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"LifeSphere\"},\"image\":{\"@id\":\"https:\/\/www.arisglobal.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/LifeSphereAG\/\",\"https:\/\/www.linkedin.com\/products\/aris-global-lifesphere\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.arisglobal.com\/#\/schema\/person\/bb2c7aafe44a090bcd667448651eb974\",\"name\":\"Mladen Prenc\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Selects ArisGlobal's Next-Gen Safety Platform LifeSphere MultiVigilance | ArisGlobal","description":"The U.S. FDA selects ArisGlobal\u2019s LifeSphere MultiVigilance drug safety platform to support modernization & enhancement of the FDA Adverse Event Reporting System (FAERS)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.arisglobal.com\/media\/press-release\/fda-selects-arisglobal-next-generation-safety-platform-lifesphere-multivigilance\/","og_locale":"en_US","og_type":"article","og_title":"FDA Selects ArisGlobal's Next-Generation LifeSphere Safety and Medical Affairs Platform","og_description":"The U.S. FDA selects ArisGlobal\u2019s LifeSphere MultiVigilance drug safety platform to support modernization & enhancement of the FDA Adverse Event Reporting System (FAERS)","og_url":"https:\/\/www.arisglobal.com\/media\/press-release\/fda-selects-arisglobal-next-generation-safety-platform-lifesphere-multivigilance\/","og_site_name":"ArisGlobal","article_publisher":"https:\/\/www.facebook.com\/LifeSphereAG\/","article_published_time":"2018-11-27T04:52:12+00:00","author":"Mladen Prenc","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Mladen Prenc","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.arisglobal.com\/media\/press-release\/fda-selects-arisglobal-next-generation-safety-platform-lifesphere-multivigilance\/#article","isPartOf":{"@id":"https:\/\/www.arisglobal.com\/media\/press-release\/fda-selects-arisglobal-next-generation-safety-platform-lifesphere-multivigilance\/"},"author":{"name":"Mladen Prenc","@id":"https:\/\/www.arisglobal.com\/#\/schema\/person\/bb2c7aafe44a090bcd667448651eb974"},"headline":"FDA Selects ArisGlobal’s Next-Generation LifeSphere Safety and Medical Affairs Platform","datePublished":"2018-11-27T04:52:12+00:00","dateModified":"2018-11-27T04:52:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.arisglobal.com\/media\/press-release\/fda-selects-arisglobal-next-generation-safety-platform-lifesphere-multivigilance\/"},"wordCount":373,"publisher":{"@id":"https:\/\/www.arisglobal.com\/#organization"},"articleSection":["Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.arisglobal.com\/media\/press-release\/fda-selects-arisglobal-next-generation-safety-platform-lifesphere-multivigilance\/","url":"https:\/\/www.arisglobal.com\/media\/press-release\/fda-selects-arisglobal-next-generation-safety-platform-lifesphere-multivigilance\/","name":"FDA Selects ArisGlobal's Next-Gen Safety Platform LifeSphere MultiVigilance | ArisGlobal","isPartOf":{"@id":"https:\/\/www.arisglobal.com\/#website"},"datePublished":"2018-11-27T04:52:12+00:00","dateModified":"2018-11-27T04:52:12+00:00","description":"The U.S. FDA selects ArisGlobal\u2019s LifeSphere MultiVigilance drug safety platform to support modernization & enhancement of the FDA Adverse Event Reporting System (FAERS)","breadcrumb":{"@id":"https:\/\/www.arisglobal.com\/media\/press-release\/fda-selects-arisglobal-next-generation-safety-platform-lifesphere-multivigilance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.arisglobal.com\/media\/press-release\/fda-selects-arisglobal-next-generation-safety-platform-lifesphere-multivigilance\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.arisglobal.com\/media\/press-release\/fda-selects-arisglobal-next-generation-safety-platform-lifesphere-multivigilance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.arisglobal.com\/"},{"@type":"ListItem","position":2,"name":"FDA Selects ArisGlobal’s Next-Generation LifeSphere Safety and Medical Affairs Platform"}]},{"@type":"WebSite","@id":"https:\/\/www.arisglobal.com\/#website","url":"https:\/\/www.arisglobal.com\/","name":"ArisGlobal","description":"","publisher":{"@id":"https:\/\/www.arisglobal.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.arisglobal.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.arisglobal.com\/#organization","name":"LifeSphere","url":"https:\/\/www.arisglobal.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arisglobal.com\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"LifeSphere"},"image":{"@id":"https:\/\/www.arisglobal.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/LifeSphereAG\/","https:\/\/www.linkedin.com\/products\/aris-global-lifesphere\/"]},{"@type":"Person","@id":"https:\/\/www.arisglobal.com\/#\/schema\/person\/bb2c7aafe44a090bcd667448651eb974","name":"Mladen Prenc"}]}},"_links":{"self":[{"href":"https:\/\/www.arisglobal.com\/wp-json\/wp\/v2\/posts\/19803"}],"collection":[{"href":"https:\/\/www.arisglobal.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.arisglobal.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.arisglobal.com\/wp-json\/wp\/v2\/users\/27"}],"replies":[{"embeddable":true,"href":"https:\/\/www.arisglobal.com\/wp-json\/wp\/v2\/comments?post=19803"}],"version-history":[{"count":0,"href":"https:\/\/www.arisglobal.com\/wp-json\/wp\/v2\/posts\/19803\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.arisglobal.com\/wp-json\/wp\/v2\/media?parent=19803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.arisglobal.com\/wp-json\/wp\/v2\/categories?post=19803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.arisglobal.com\/wp-json\/wp\/v2\/tags?post=19803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}